ONK Therapeutics Snags $21.5M for NK Cell Therapies

San Diego- and Galway, Ireland-based ONK Therapeutics announced today that it has raised $21.5M in its Series A funding. The funding was led by Acorn Bioventures and ALSHC, plus Cormorant Asset Management. The startup says it is developing optimally engineered natural killer (NK) cell therapies. ONK said the new funding will go to drive multiple, pre-clinical programs through IND-enabling studies, and also go towards GMP manufacturing capability. The company’s CEO is Chris Nowers.